Travere Therapeutics to Report Third Quarter 2026 Financial Results
Travere Therapeutics Inc Ordinary Shares TVTX
News
Travere Presents New Biomarker Data at ASN Kidney Week Suggesting FILSPARI® (sparsentan) May Modify Underlying Disease Pathophysiology in IgA Nephropathy
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Travere to Present New Data Supporting FILSPARI® (sparsentan) as Foundational Treatment in IgA Nephropathy and FSGS at ASN Kidney Week 2026
Kuehn Law Encourages Investors of Travere Therapeutics, Inc. to Contact Law Firm
Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in Focal Segmental Glomerulosclerosis
Travere Therapeutics Announces Planned Chief Executive Officer Transition
Travere Therapeutics to Present at the Stifel 2026 Virtual Immunology and Inflammation Forum
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Travere Therapeutics to Participate at Upcoming Investor Conferences
Travere Therapeutics Reports Second Quarter 2026 Financial Results
Travere Therapeutics Shares Rise on FDA Approval of Kidney-Disorder Drug
Travere Therapeutics Gets FDA Approval for Kidney Disorder Treatment
Travere Therapeutics Shares Fall After FDA Extends Filspari Review
United States